Description
Dermatomyositis is an autoimmune inflammatory condition characterized by muscle weakness and distinctive skin rashes. Diagnosing dermatomyositis can be challenging due to overlapping symptoms with other autoimmune diseases.
The Dermatomyositis Autoantibody Panel is a blood test that detects specific autoantibodies associated with dermatomyositis and related inflammatory muscle diseases. Identifying these autoantibodies helps confirm diagnosis, guides treatment, and predicts disease course.
What Does This Panel Test For?
This panel measures multiple autoantibodies commonly found in patients with dermatomyositis and other inflammatory myopathies, including:
- Anti-Mi-2: Associated with classic dermatomyositis with prominent skin involvement and better prognosis.
- Anti-TIF1-gamma (p155/140): Linked to cancer-associated dermatomyositis.
- Anti-NXP-2 (MJ): Seen in juvenile and adult dermatomyositis, associated with calcinosis and severe muscle disease.
- Anti-MDA5 (CADM-140): Linked to clinically amyopathic dermatomyositis and interstitial lung disease risk.
- Anti-SAE: Associated with skin-predominant dermatomyositis.
- Anti-SRP: Typically related to immune-mediated necrotizing myopathy, sometimes overlapping with dermatomyositis.
- Anti-HMGCR: Related to statin-associated autoimmune myopathy.
Who Should Consider This Test?
- Patients presenting with muscle weakness and skin rashes suggestive of dermatomyositis
- Individuals with unexplained muscle inflammation or elevated muscle enzymes (CK)
- Patients with suspected autoimmune myopathies or overlap syndromes
- Those undergoing evaluation for cancer-associated myositis
- Patients with interstitial lung disease and suspected autoimmune etiology
Test Details
- Sample Type: Serum (blood draw)
- Fasting Required: No fasting required
